Molecular sciences a novel triple-action inhibitor targeting b-cell receptor signaling and brd4 demonstrates preclinical activity in audrey l

HIGHLIGHTS

• who: BTK et al. from the Eppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, Department of Biostatistics, College of Public Health, University of Nebraska Medical Center have published the article: Molecular Sciences A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Audrey L, in the Journal: (JOURNAL)
• what: The authors demonstrate that SRX3305 a novel small-molecule BTK/PI3K/BRD4 inhibitor that targets three distinctive facets of CLL biology attenuates CLL cell proliferation and promotes apoptosis in a dose-dependent fashion . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.